Asset Details
Do you wish to reserve the book?
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma
Do you wish to request the book?
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma
2018
Overview
Background
The relevance of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Clinical trials targeting ER with selective estrogen receptor modulators in pancreatic cancer did not show any benefit. Here, we analyze the impact of recently characterized ER isoform beta on survival in a cohort of patients with resected PDAC.
Methods
Eighty-four patients having undergone pancreatic resection for PDAC at a single institution were identified. Tissue microarrays were constructed of archival tumor specimens. The expression of ER beta was determined by immunohistochemistry and quantified by a system established for estrogen receptor expression in breast cancer. ER beta expression was then correlated with clinicopathological parameters, and univariate and multivariate survival analyses were performed.
Results
Nuclear expression of ER beta was found in 31% of tumors. No significant correlation was found between ER beta expression and TNM status, tumor grade, age or sex. Univariate analysis revealed nodal metastasis and the expression of ER beta as factors correlating with a shorter overall survival and disease free survival. When comparing ER beta expression in patients surviving more than 24 months with those who died from the tumor within 12 or 24 months, respectively, a significantly lower ER beta expression was found in the long term survivors. In multivariate analysis, ER beta expression was demonstrated to be an independent predictor of shorter overall survival.
Conclusions
In resected PDAC, expression of ER beta seems to correlate with poor prognosis. These data may help to identify patients who may benefit from additional systemic therapy including selective estrogen receptor modulators.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Aged
/ Biomedical and Life Sciences
/ Estrogen
/ Estrogen Receptor beta - genetics
/ Estrogen Receptor beta - metabolism
/ Female
/ Gene Expression Regulation, Neoplastic
/ Health Promotion and Disease Prevention
/ Humans
/ Male
/ Oligonucleotide Array Sequence Analysis
/ Oncology
/ Pancreatic ductal adenocarcinoma
/ Pancreatic Neoplasms - genetics
/ Pancreatic Neoplasms - mortality
/ Pancreatic Neoplasms - pathology
/ Pancreatic Neoplasms - surgery
/ Selective estrogen receptor modulators
/ Surgery
/ Surgical oncology and imaging
/ Survival
/ Tumors
